DiaSys Announces New Distributorship Agreements in the Middle East and Pakistan as Infectious Disease Diagnostic Markets Grow in Parasitic Infections Including Malaria & Leishmania.Business Editors/Health/Medical Writers WATERBURY, Conn.--(BUSINESS WIRE)--May 17, 2004 DiaSys Corporation (AMEX AMEX See: American Stock Exchange :DYX DYX Dyslexia ), a global healthcare products company, today announced, through its subsidiary DiaSys Europe, that it had recently made new distributorship agreements in Kuwait, Oman, Bahrain and Pakistan. Distributors in each of these countries will exclusively promote, sell and service DiaSys diagnostic products through their network of a direct salesforce and sub-distributors. These products include the DiaSys Parasep system of single-use containers for the collection, filtration and analysis of parasites in human body fluids, the DiaSys "FE" Series Workstations used to analyze human body fluids for parasites, the DiaSys R/S R/S Remote Sensing R/S Rally Sport R/S Respectfully Submit R/S Report of Survey R/S Route Sheet R/S Reentry System R/S Revision Segment R/S Rationalization & Standardization R/S Regulatory or Safety (automotive requirements) 2003 Workstations for urine sediment analysis and a wide range of rapid-tests for fast screening of a significant range of infectious diseases. John Aspden, Director of Sales & Marketing, DiaSys Europe, said: "Pakistan and the Middle East provides us with significant opportunities, especially for our successful parasitology Parasitology The scientific study of parasites and of parasitism. Parasitism is a subdivision of symbiosis and is defined as an intimate association between an organism (parasite) and another, larger species of organism (host) upon which the parasite is product range and once again shows the suitability of our products for a global market. The drive for standardization and accreditation by government healthcare ministries provides us with additional market-pull in these countries. With the changing dynamics of increased international travel, immigration immigration, entrance of a person (an alien) into a new country for the purpose of establishing permanent residence. Motives for immigration, like those for migration generally, are often economic, although religious or political factors may be very important. and World Health Organisation (WHO) drives to eradicate major diseases such as malaria, leishmania Leishmania /Leish·ma·nia/ (lesh-ma´ne-ah) a genus of parasitic protozoa, including several species pathogenic for humans. In some classifications, organisms are placed in four complexes comprising species and subspecies: L. & HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome , these countries are beginning to refocus their disease prevention & diagnostic methods. Significant evaluation of product has taken place in each country and DiaSys will continue to support the development of these and newer products appropriate to the Pakistan & Middle East markets. The challenge will be to make our products fit their markets rather than the other way round." DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. test-kits to healthcare & veterinary laboratories worldwide. With its headquarters in Waterbury, Connecticut, USA, the Company also operates in Europe, Middle East, Africa & Indian Subcontinent through its wholly-owned subsidiary based in Wokingham, England, and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion